Literature DB >> 12906378

Testosterone replacement therapy in male hypogonadism.

M Byrne1, E Nieschlag.   

Abstract

In human males 6-7 mg of testosterone are secreted by the testes in a circadian rhythm with a nocturnal rise in testosterone followed by a decline during the day. Testosterone is necessary to induce and maintain secondary sexual characteristics, lean muscle mass, bone density and for normal sexual behaviour and cognitive function in men. Replacement therapy has been shown to be beneficial in men with overt hypogonadism. Natural testosterone should be used and not modified molecules. Testosterone is currently available in oral, intramuscular, subcutaneous and transdermal preparations. Recent advances in testosterone replacement therapy include testosterone gels which provide flexibility in dosing and minimal skin irritation resulting in good compliance, and the development of longer acting intramuscular preparations which result in more stable testosterone levels with longer injection intervals. All patients receiving testosterone should be carefully monitored for changes in hematocrit, liver function, lipid parameters and prostate specific antigen (PSA).This article reviews the current experience with the use of various forms of testosterone for the treatment of male hypogonadism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906378     DOI: 10.1007/bf03345206

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  52 in total

1.  Effect of testosterone treatment on bone mineral density in men over 65 years of age.

Authors:  P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

2.  CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men.

Authors:  Ewa Rajpert-De Meyts; Henrik Leffers; Jørgen H Petersen; Anne Grethe Andersen; Elisabeth Carlsen; Niels Jørgensen; Niels E Skakkebaek
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

4.  Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.

Authors:  C Wang; D R Eyre; R Clark; D Kleinberg; C Newman; A Iranmanesh; J Veldhuis; R E Dudley; N Berman; T Davidson; T J Barstow; R Sinow; G Alexander; R S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

5.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

6.  Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.

Authors:  Sigrid von Eckardstein; Eberhard Nieschlag
Journal:  J Androl       Date:  2002 May-Jun

7.  Obstructive sleep apnea syndrome induced by testosterone administration.

Authors:  R E Sandblom; A M Matsumoto; R B Schoene; K A Lee; E C Giblin; W J Bremner; D J Pierson
Journal:  N Engl J Med       Date:  1983-03-03       Impact factor: 91.245

8.  A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.

Authors:  L P Ly; M Jimenez; T N Zhuang; D S Celermajer; A J Conway; D J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

9.  Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male.

Authors:  T Mulligan; A Iranmanesh; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

10.  Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels.

Authors:  G R Cunningham; E Cordero; J I Thornby
Journal:  JAMA       Date:  1989-05-05       Impact factor: 56.272

View more
  5 in total

Review 1.  The endocrine pharmacology of testosterone therapy in men.

Authors:  Michael Oettel
Journal:  Naturwissenschaften       Date:  2004-01-28

2.  Hypertrophy with unilateral resistance exercise occurs without increases in endogenous anabolic hormone concentration.

Authors:  Sarah B Wilkinson; Mark A Tarnopolsky; Emily J Grant; Caroline E Correia; Stuart M Phillips
Journal:  Eur J Appl Physiol       Date:  2006-09-14       Impact factor: 3.078

3.  The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.

Authors:  Barbara J Attardi; Sheri A Hild; Sailaja Koduri; Trung Pham; Laurent Pessaint; Jean Engbring; Bruce Till; David Gropp; Anne Semon; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-25       Impact factor: 4.292

4.  Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.

Authors:  Barbara J Attardi; Trung C Pham; Lisa C Radler; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2008-06       Impact factor: 4.292

Review 5.  Pharmacology of testosterone replacement therapy preparations.

Authors:  Jennifer J Shoskes; Meghan K Wilson; Michael L Spinner
Journal:  Transl Androl Urol       Date:  2016-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.